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Abstract
Introduction: This study describes the results of the Belgian ‘MabThera In Rheumatoid Arthritis (MIRA)’ registry:
effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian
reimbursement criteria for rituximab.
Methods: All Belgian rheumatologists had the possibility to participate in the study. Patients entered the registry in
November 2006 and the entry is still open.
Results: By mid-September 2009, 401 patients had entered the registry with a mean follow-up time of 70 weeks.
Overall, DAS28-ESR decreased from 6.0 at baseline to 4.2 at week 16. Further decrease of disease activity was
observed at the end of year 1 and year 2 with mean DAS28-ESR of 4.0 and 3.7 at these respective time points.
More than 80% of patients showed a EULAR response at week 16. Patients could be retreated if they had DAS
scores of > 3.2 at least 6 months after the previous course. Second and third courses were given in 224 and 104
patients, respectively. At month 6 after the second course, significantly lower DAS28-ESR values were observed
compared to the first course. This was especially the case for patients who were retreated before they showed an
obvious flare (DAS increase > 1.2).
Conclusions: This study describes the follow-up of a daily clinical practice cohort of 401 RA patients with long-
standing refractory disease treated with rituximab. Relatively high DAS28 values at the start of each retreatment,
compared to values 6 months after each treatment course, were noted. Moreover, further decrease of DAS28
scores after the second course was significantly more pronounced in those patients who didn’t show an obvious
flare. These two elements suggest that treatment of RA patients with rituximab could be optimized by earlier
retreatment.
Introduction
Rituximab (RTX), which has been available for the treat-
ment of lymphoma since 1998, was approved in 2006
for the treatment of rheumatoid arthritis (RA) patients
who failed tumor necrosis factor (TNF)-alpha blockers
[1]. The need for treatment beyond TNF blockers in RA
has become clear since 25% to 40% of patients in clini-
cal trials fail to achieve an ACR-20 (American College
of Rheumatology 20% improvement criteria) response
[2-4] and a proportion of patients experience treatment-
limiting side effects or continue to experience a residual
level of disease activity or show flares under anti-TNF
therapy.
RTX is a genetically engineered chimeric monoclonal
antibody. It binds to the antigen CD20, which regulates
cell cycle initiation and differentiation and is found in
normal and malignant pre-B and mature B lymphocytes
[5,6]. The safety, effectiveness, and prevention of radi-
ological progression by RTX treatment in patients with
RA have been proven previously [1,7-9].
The standard course of RTX consists of two 1,000-mg
intravenous infusions with an interval of 2 weeks
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6 and 12 months after the first course. There is increas-
ing evidence that treatment with repeated courses of
RTX over a longer follow-up period is safe and well tol-
erated [10,11]. However, the retreatment protocol that
should be used is still a matter of debate [12].
On the basis of existing evidence about effectiveness,
safety, and costs and of approvals by the European
Medicines Agency (EMEA) and US Food and Drug
Administration (FDA), most countries have developed
s p e c i f i cc r i t e r i af o ru s eo fR T Xi nR A .I nB e l g i u m ,
patients are eligible for RTX treatment if they failed at
least one anti-TNF and have a baseline DAS28 (disease
activity score using 28 joint counts) of more than 3.7.
From week 24, patients may receive further courses of
RTX treatment if they had a moderate or good EULAR
(European League Against Rheumatism) response at
week 16 of the first treatment course and a current
DAS28 of at least 3.2. The aims of this study were to
evaluate the effectiveness, attrition, and reasons for dis-
continuation of RTX treatment in daily clinical practice
within the reimbursement criteria and to evaluate these
criteria.
Materials and methods
Study population
The Belgian MIRA (MabThera In Rheumatoid Arthritis)
cohort is supported by the Royal Belgian Society for
Rheumatology (KBVR/SRBR) via a grant from Roche
(Basel, Switzerland). The first patients were recruited in
the cohort in November 2006 and recruitment is still
open. Recruitment is open to all rheumatologists from
Belgium and Luxemburg and covers more than 40% of
all academic and non-academic rheumatology centers in
those countries.
A specific clinical record file was designed for this
study. Baseline variables capture demographics, disease
duration, rheumatoid factor and anti-CCP (anti-cyclic
citrullinated peptide) status, and (RA) medication his-
tory. Additional clinical data are captured at baseline
and every 8 weeks from week 16 onwards. These clinical
data include the 28 and 66/68 swollen and tender joint
counts, erythrocyte sedimentation rate (ESR) (milli-
meters per hour), C-reactive protein (CRP) (milligrams
per liter), patient global visual analog scale (VAS),
changes in therapy, and (where applicable) the reason
that led to discontinuation; ineffectiveness, safety, elec-
tive, and death were predefined in the clinical record
file. ‘Lost to follow-up’ was queried if no data were
available at 1 year.
One course of RTX consists of two 1,000-mg infusions
RTX with an interval of 2 weeks between each infusion.
Prior to the RTX infusion, patients receive 1 g of para-
cetamol, an antihistaminic (mostly 10 mg cetirizine),
and 100 mg methylprednisolon. The study was approved
by all ethical committees concerned, and all patients
provided written informed consent before recruitment.
Statistical data analysis
Descriptive analyses were performed by the calculation
of means, mean differences (mean diffs), and propor-
tions. Differences between subgroups were analyzed by
(paired) t tests for continuous variables and chi-square
tests for dichotomous variables. Ordinal data were ana-
lyzed by the calculation of the gamma statistic. Compar-
isons between DASs at similar time points from
different courses were evaluated by the calculation of
differences of means and paired t tests. The analysis of
different events over time was performed by Kaplan-
Meier curves and log-rank tests. Unbalanced data were
balanced to an interval of 4 weeks, and missingness
completely at random was assumed, and a sensitivity
analysis assuming missingness at random was also per-
formed. Statistical analysis was performed with SPSS 17
(SPSS Inc., Chicago, IL, USA). DAS28-ESR values were
calculated [13]. A substantial flare was defined as the
increase of the DAS28 of at least 1.2 points.
Results
Description of the population
By September 2009, data from 401 patients were
included in the database with a mean follow-up time of
70 weeks (range 0 to 146 weeks). Patients had a mean
age of 59 years (standard deviation 13 years), 76% were
female, and the mean disease duration was 12 years
(Table 1). The mean DAS28 at baseline was 6.0 (stan-
dard error [SE] = 0.1). Second and third courses were
given in 224 and 104 patients, respectively.
Attrition and reasons for discontinuation
Forty-seven patients (12%) discontinued treatment at a
median follow-up time of 40 weeks; 30 patients (8%)
Table 1 Baseline characteristics
Number of patients 401
Age, years 59 (SE 0.6)
Female 76%
Disease duration, years 12 (SE 0.5)
DAS28-ESR at baseline 6.0 (SE 0.1)
RF-positive 81%
Anti-CCP-positive 81%
No previous biologicals 3%
One previous biological 47%
Two previous biologicals 34%
More than two previous biologicals 15%
Anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity
score using 28 joint counts; ESR, erythrocyte sedimentation rate; RF,
rheumatoid factor; SE, standard error.
Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R169
http://arthritis-research.com/content/12/5/R169
Page 2 of 7discontinued because of ineffectiveness and 17 (4%) dis-
continued because of safety issues. Infusion reactions
leading to discontinuation were reported in 6 patients,
infections were reported in 4 patients (3 with pneumo-
nia and 1 with recurrent minor infections), and other
diverse safety reasons were reported in the remaining
7 patients: the evolution of a pre-existing malignancy in
2 patients (lymphoma and myeloma), leucopenia, med-
iastinal adenopathies, hair loss, unexplained pain over
the body, and hallucinations. One patient died after
pneumonia in relation to a hip fracture. Fifteen patients
(3.7%) were lost to follow-up.
Effectiveness
Evolution of disease activity for the cohort
Overall, treatment with RTX decreased the cohort’s
mean disease activity, measured by DAS28-ESR, from
6.0 (SE = 0.1) at baseline to 4.2 (SE = 0.1) at week 16.
Eighty-two percent of patients obtained a EULAR
response at week 16. Further decrease of disease activity
of the cohort was observed at the end of year 1 and
year 2 with mean DAS28-ESR values of 4.0 (SE = 0.2)
and 3.7 (SE = 0.2), respectively. All four parameters of
the DAS28, including the parameters of inflammation,
showed a similar trend of decrease over the time: mean
ESR values decreased from 38 (SE = 1) to 23 (SE = 2)
after 1 year (P < 0.001), and mean CRP values decreased
from 28 mg/L (SE = 2) to 15 mg/L (SE = 3) (P = 0.005).
Evolution of disease activity over the different courses
At the start of each treatment course, the DAS28-ESR
values were lower than values at the start of the pre-
vious treatment course. The values reached a minimum
at week 16 of each respective treatment course and then
increased slightly by week 24 (from week 24 onwards,
patients were eligible for retreatment but were not
necessarily immediately retreated). From the 24th week,
the values further increased until the start of the follow-
ing treatment course (Figure 1).
Figure 1 DAS28-erythrocyte sedimentation rate values at baseline, week 16, and week 24 of each respective treatment course. Four
hundred one patients started rituximab treatment. Second and third courses were given in 224 and 104 patients, respectively. CI, confidence
interval; DAS28, disease activity score using 28 joint counts.
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first and second courses suggests that lower DASs are
obtained after the second course (mean diff at week 16
=0 . 0 4 ,S E=0 . 2 ,P = 0.003; mean diff at week 24 =
−0.7, SE = 0.2, P < 0.001) (Figure 1). This further
decrease of DAS28 between the first and second courses
was significantly more pronounced in those patients
who did not flare (defined as an increase of DAS28 of
greater than 1.2) between week 24 and their second
course (mean diff = −1.2, SE = 0.2 versus mean diff 0.2,
SE = 0.4, P = 0.002). These paired evaluations were per-
formed only in those patients who had received at least
two courses and had a follow-up after the second course
of at least 24 weeks (Figures 2 and 3).
Similarly, when DAS values were categorized, DAS28-
ESR values shifted from higher disease activity segments
to lower disease activity segments at each treatment
course (Figure 2). At baseline of the first treatment
course, 81% of the patients had a high disease activity
(DAS of greater than 5.1). This percentage dropped to
22% at 16 weeks, with 23% of patients reaching a remis-
sion or low disease activity status (DAS of less than 3.2)
at 16 weeks.
At baseline of the second treatment course, 57% of
patients had a high disease activity that dropped to 14%
at 16 weeks, with 28% reaching a remission or low dis-
ease activity status at 16 weeks. Six months after the
first and second courses, 80% and 68% of patients,
respectively, had at least a moderate disease activity
(Figure 2). Second and third courses were given in 224
and 104 patients, respectively.
Previous use of anti-tumor necrosis factor
Data about previous anti-TNF use indicate that the use of
RTX is clearly shifting from the use after more anti-TNFs
to the use after only one anti-TNF (Figure 4). There was a
trend toward lower EULAR response rates at week 16 in
patients who failed more than one anti-TNF. Thirty-two
percent of patients who failed three anti-TNFs had no
response at week 16 in contrast to 13% in patients who
failed only one anti-TNF (gamma = −0.22, SE = 0.10,
P = 0.043) (Table 2).
Discussion
This study describes the follow-up of a cohort of 401
RA patients with longstanding refractory disease treated
with RTX in combination with methotrexate. These
patients are treated and followed in a daily clinical prac-
tice setting at different rheumatology centers in Belgium
or Luxemburg. The high coverage of this study by the
different rheumatologists and the low percentage of ‘lost
to follow-up’ (3.7%) suggest a good representation of the
patients who are candidates for this treatment.
At week 16, 82% of patients obtained a good or moder-
ate EULAR response, with 23% of patients reaching a
remission or low disease activity status after only one
treatment course and 28% to 32% (week 16 and week 24)
after the second treatment course. This suggests that the
Figure 2 Proportions of patients in each disease activity score category at baseline, week 16, and week 24 of courses 1 and 2. Four
hundred one patients started rituximab treatment. Second and third courses were given in 224 and 104 patients, respectively. DAS28, disease
activity score using 28 joint counts.
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daily clinical practice setting to the effectiveness seen in
more controlled (open-label and placebo-controlled)
trials and studies [1,8].
Moreover, even lower DAS values can be obtained
after a second course of RTX: paired analysis of DASs
at week 16 and week 24 from the first and second
courses showed significantly lower DASs after the sec-
ond course of RTX. This is especially the case for
patients who were retreated before they flared. A further
decrease of disease activity after the second course has
been previously suggested [10], but limited data are
available on the effect of retreatment before flare. One
controlled trial suggested no difference in response
between fixed versus on-demand retreatment strategies
[12]. However, recently presented retrospective data [14]
and unpublished data from a randomized controlled
trial [15] suggest a clear difference between the efficacies
of the two approaches. Thurlings and colleagues [16]
demonstrated that, when a systematic retreatment
approach was applied, a second RTX course in first-
course responders resulted in a further decrease of
DAS28 of 1.2 points.
The data from the present study suggest that lower
cumulative DAS values can be obtained if patients with a
DAS28 of more than 3.2 are retreated before they show a
substantial flare. The further DAS28 decrease in these
patients (−1.2) is comparable to the DAS28 decrease
reported by Thurlings and colleagues [16] when a sys-
tematic retreatment approach was applied. Overall, sys-
tematic retreatment if patients show a DAS28 of more
than 3.2 is in line with the concept of DAS-driven tight
control of the disease; at the moment, this seems to be the
best strategy to induce persistent low disease activity, at
least in patients with early RA [17]. Therefore, the possibi-
lity of a systematic retreatment after 6 months in patients
with a residual disease activity of more than 3.2 is an
important aspect of the current reimbursement criteria.
It has been suggested that the number of failed anti-
TNFs and the serological status are predictors of
response to RTX therapy [18]. In this study, we con-
firmed that the number of previously failed anti-TNFs
was significantly associated with response to the first
course of RTX: 32% of patients who failed three anti-
TNFs had no response at week 16 in contrast to 13% in
patients who failed only one anti-TNF. Previous reports
suggested that the switch to RTX after failing one anti-
TNF may be more effective than switching to an alter-
native anti-TNF agent in patients with an inadequate
response to anti-TNFs [19,20]. These data, together with
Figure 3 Evolution of disease activity scores from week 24 on
after retreatment in patients with or without flare. CI,
confidence interval.
Figure 4 Number of previously failed anti-tumor necrosis factors (anti-TNFs) in function of time era.
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observation that the proportions of patients who failed
three anti-TNFs before starting RTX have been decreas-
ing over the years in favor of a switch after failure of
one or two anti-TNFs.
In line with previous data [10,21], RTX appears to be
safe: 17 (4.3%) patients discontinued because of safety
issues (the most prevalent of which was allergic infusion
reaction). Infections were reported in 4 patients (3 with
pneumonia and 1 with recurrent minor infections). One
patient died following pneumonia in relation to a hip
fracture. No cases of progressive multiple leukoencepha-
lopathy were seen in this cohort [22].
This study has strengths and weaknesses. Similar to all
observational studies, this study may suffer from expecta-
tion bias, leading to an overestimation of the response
rates to RTX therapy. Additionally, there was no protocol
guiding the decision for retreating patients (and this has
led to heterogeneity between centers and patients) or the
evolutions of treatment strategies over time. It is especially
important to notice that, following the Belgian reimburse-
ment criteria in the present study, patients could be
retreated only if they showed a remaining disease activity
of greater than 3.2. Therefore, the potential benefit of sys-
tematic retreatment could be evaluated only in patients
with at least moderate remaining disease activity. The
strength of this study is that the registry was open to all
Belgian and Luxembourgian rheumatologists, resulting in
a high participation rate of small and large rheumatology
centers. Consequently, this study gives a representative
view of the daily clinical practice use of RTX.
Conclusions
From this daily clinical practice cohort, some recom-
mendations for the optimization of RTX treatment stra-
tegies can be given: If patients can be retreated before
they show an obvious flare, a more pronounced further
decrease of disease activity can be observed. Therefore,
systematic retreatment of patients with a remaining dis-
ease activity of DAS greater than 3.2 should be consid-
ered. Also, as DAS values may further decrease after the
second course, a switch to another treatment strategy
for unacceptable remaining disease activity should be
considered at the earliest after the second course.
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Table 2 EULAR response in function of the number of previously failed anti-TNFs
Number of previously failed anti-TNFs EULAR response at week 16
No response Moderate response Good response
1( n = 99) 13.1% 59.6% 27.3%
2( n = 72) 18.1% 58.3% 23.6%
3( n = 31) 32.3% 51.6% 16.1%
EULAR, European League Against Rheumatism; TNF, tumor necrosis factor.
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